Endo Health Solutions said today it is acquiring Canadian-based specialty pharma company Paladin Labs for roughly $1.6 billion, in a stock and cash deal that expands the buyer’s global presence, ...

Endo International (ENDP) announced that it has completed the acquisition of Paladin Labs (PLDLF) in a stock and cash transaction currently valued at approximately $2.7B. The acquisition accelerates ...

Endo Health Solutions (NASDAQ:ENDP) has agreed to acquire Canadian peer Paladin Labs (PLDLF) for about $1.6B in a cash and stock deal that will expand Endo's presence in emerging markets as well as in ...

DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

The acquisition accelerates Endo's strategic transformation to a leading global specialty healthcare company and creates a platform for future growth in North America and internationally. Pursuant to ...

MALVERN, Pa. — Endo Health Solutions will acquire Canadian drug maker Paladin Labs for $1.6 billion, mostly in shares of stock, Endo said Tuesday. Endo said the acquisition would accelerate its ...

Endo Health Solutions ($ENDP) needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company ...

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed ...

DUBLIN and LUGANO, Switzerland, July 31, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are ...

MALVERN, Pa. (AP) -- Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly-formed Irish holding company. Endo also ...

Endo Health Solutions Inc. ENDP agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. (PLDLF, PLB.T) for about $1.6 billion, allowing Endo to continue its transition into a ...

Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company Creates a compelling financial and operational platform for future growth Establishes Endo's global ...